Epstein-Barr virus (EBV) is a human herpesvirus which infects lymphoid and epithelial cells. This virus is the aetiological agent of infectious mononucleosis and is implicated in nasopharyngeal carcinoma, Hodgkin's disease and Burkitt's lymphoma (Rickinson & Kieff, 1996) . After infection of B lymphocytes, EBV immortalizes the cells and is maintained in a latent condition. Latency can be disrupted by treating the infected cells with phorbol esters, sodium butyrate or antiimmunoglobulin (Faggioni et al., 1986 ; Luka et al., 1979 ; Takada & Ono, 1989 ; zur Hausen et al., 1978) . Such treatment causes cells to express two viral immediate-early genes, BRLF1 and BZLF1. Expression of these two is necessary for the activation of EBV early genes and virus lytic replication (Biggin et al., 1987 ; Hardwick et al., 1988 ; Sinclair & Farrell, 1992) . At the latter stage of EBV lytic development, the late genes, including BcLF1 which encodes viral capsid antigen (VCA), are expressed (Baer et al., 1984) . Previous studies have shown that expression of BcLF1 is prevented by inhibitors of EBV DNA polymerase, including phosphonoacetic acid (PAA), phosphonoformic acid and acyclovir (Datta & Hood, 1981 ; Summers & Klein, 1976) , suggesting that expression of BcLF1 may rely on EBV DNA replication. A recent study suggests Author for correspondence : Shih-Tung Liu.
Fax j886 3 328 0292. e-mail cgliu!cguaplo.cgu.edu.tw that transcription of BcLF1 may require a trans factor (Serio et al., 1997) . In this study, we analyse the BcLF1 promoter and define the region which is necessary to regulate transcription of BcLF1.
We first determined the transcription start site of BcLF1 mRNA by primer extension. This was done with the primer 5h GTCTCGAGGGCTTCTCTTCACAGCTG, which is complementary to the 5h region of BcLF1 (nt 137496-137521 of the EBV genome). Primer extension was performed with 100 µg of total RNA isolated from P3HR1 cells which had been treated with 12-O-tetradecanoylphorbol 13-acetate (TPA) (30 ng\ml) and sodium butyrate (3 mM) for 2 days. Next, the primer (100 ng) was end-labelled (Sambrook et al., 1989) with 5 µCi [γ-$#P]ATP (5000 Ci\mmol) (Amersham) and 10 U of T4 polynucleotide kinase (Promega). The radioactively labelled primer was then annealed with RNA template at 65 mC for 20 min and then incubated at 37 mC for 2 h. Reverse transcription was performed with 1 U of AMV reverse transcriptase (Promega) at 42 mC for 30 min. The cDNA synthesized was precipitated by ethanol and was then analysed in an 8 % (w\v) acrylamide sequencing gel (Sambrook et al., 1989) . DNA sequencing was performed with the same primer by the dideoxy chain termination method (Sanger et al., 1977) , using pVCAluc (see below) as a template. According to our results, the j1 site is located at nucleotide position 137676 ( Fig. 1 ). This was confirmed with a second primer, 5h GGTCTGTTTTCCAC-ACCCTCATTTGAGGC, complementary to the region between nt 137435-137463. Sequence analysis revealed that a TATA sequence is located between nt k34 and k28 and that a YY1-like sequence, GGACCATATTTC (Mills et al., 1994 ; Shi et al., 1991) , is located between nt k109 and k98. The initiation codon of BcLF1 is located at position j211. We constructed a reporter plasmid, pVCAluc, to analyse the BcLF1 promoter. A luc fragment, isolated from pGL2-Basic (Promega) by HindIII\BamHI digestion, was filled-in with Klenow fragment of DNA polymerase (Promega) and inserted into the T4 DNA polymerase-treated KpnI site of pGEM7Zf(k) (Promega) to generate plasmid pGEM-luc. Next, the promoter and the untranslated region of BcLF1, from nt k416 to j210, was amplified by PCR with primers 5h GAATG-TGCTCCAGGAGAAGAAGTGG and 5h GACACAAGGT-AAGAGGGAGATGG, and was inserted upstream from the luc gene at the SmaI site of pGEM-luc. The subsequent plasmid, pVCAluc (10 µg), was transfected into P3HR1 cells, and the cells were treated with TPA and sodium butyrate immediately after transfection. The luciferase activity exhibited by the plasmid was examined 2 days after transfection. Cell lysate was prepared 48 h after transfection and luciferase activity was monitored for 10 s with a luminometer (Berthod model LB953) according to a method described by de Wet et al. (1987) . Each transfection experiment was repeated at least three times, and each sample was prepared in duplicate. Under lytic conditions, pVCAluc exhibited approximately 10-fold higher luciferase activity than control plasmid pGEM-luc (Fig. 2 b) . Under latent conditions, the activity exhibited by pVCAluc was approximately 20-fold lower (Fig. 3) , showing that the BcLF1 promoter is active only under lytic conditions. Next, we generated mutations to determine the region essential for the regulation of BcLF1 expression. These deletions (Fig. 2 a) included ∆BamHI, ∆SmaI, ∆AvaII, ∆StyI and ∆MluI, which were generated by restriction digestion of pVCAluc ; ∆114, ∆94, ∆38 and ∆9, which were constructed by inserting PCR fragments into the SmaI site of pGEM-luc ; S-P and S-M, which were generated by PvuII and MluI digestion of ∆StyI, respectively ; and F53 and F23, which were generated by inserting synthetic oligonucleotides into the SmaI site of pGEM-luc. Under latent conditions the plasmids described above exhibited luciferase activity at the background level (data not shown), in a similar way to pVCAluc. This implies that the deleted regions do not contain any sequence that would negatively regulate the expression of BcLF1 under latent conditions. On the other hand, these plasmids displayed different patterns of expression under lytic conditions. According to our results, deleting the region between nt k416 and k38, including ∆BamHI, ∆SmaI, ∆114, ∆AvaII, ∆94, ∆StyI and ∆38, did not influence luc expression (Fig. 2 b) .
It seems, therefore, that the sequence upstream from nucleotide k38, including the YY1 sequence, is not essential for the transcription of BcLF1. However, the luciferase activity decreased to background level (Fig. 2 b) if the regions upstream from k9 and from the MluI site (∆MluI) (Fig. 2 a) were deleted. In addition, deleting the region from nt j210 to j45 (Fig. 2 a) did not decrease luc expression (Fig. 2 b) . We also inserted the BamHI-b fragment of EBV, which covers the region between k1681 and k348, into the BamHI site (nt k347) of ∆BamHI. This insertion did not influence pVCAluc expression, indicating that the BamHI-b fragment is also not essential for transcription of BcLF1.
We deleted the sequence in the untranslated region and the 3h region of the promoter to determine whether this influenced luc expression. Oligonucleotides covering the regions between nt k38 and j15 (F53) and nt k38 and k16 (F23) were synthesized and cloned into the SmaI site of pGEM-luc (Fig.  2 a) . Both plasmids expressed luciferase activity under lytic , c) . The oriLyt fragment was inserted in opposite orientations in (b) and (c). Black column, control (cells not treated with TPA and sodium butyrate) ; grey column, cells treated with TPA and sodium butyrate ; white column, cells treated with TPA, sodium butyrate and PAA. pVCAluc ori(j), plasmid pVCAluc consisting of an oriLyt sequence with an orientation identical to that of luc ; pVCAluc ori(k), the same as pVCAluc except that the oriLyt is in the opposite orientation. pGEM-luc ori(j) and pGEM-luc ori(k), identical to pVCAluc ori(j) and pVCAluc ori(k), respectively, but without BcLF1 promoter.
conditions (Fig. 2 b) , but not under latent conditions. This suggests that the 23 bp fragment in F23 contains the sequence necessary to regulate BcLF1 transcription. Our results further verified that PAA treatment (200 µg\ml) could inhibit the transcription activity of F23 (data not shown), implying that luc expression by F23 is dependent on EBV lytic replication. Sequence analysis indicated that this 23 bp region contains a TATA sequence, but no sequence homologous to any transcription factor binding site. Exactly how transcription from this 23 bp region is regulated remains unknown. One possibility is that the promoter may contain a sequence allowing the binding of a negative regulator, which represses BcLF1 expression or prevents the binding of TFIID to the TATA sequence during latent and early lytic stages. This negative regulator may be removed after EBV lytic replication, allowing binding of TFIID to the TATA sequence to initiate the transcription of the gene. Another possibility is that transcription of BcLF1 by TFIID may require a positive factor, which is expressed only during the lytic cycle. Furthermore, the 23 bp region which regulates BcLF1 transcription closely resembles the regulatory element in the promoter of the late gene of type 1 herpes simplex virus (HSV), which also contains a TATA sequence only (Johnson & Everett, 1986) . This finding implies that these two herpesviruses may use a similar mechanism to regulate transcription of their late genes.
As is generally known, the expression of BcLF1 depends on lytic replication of the EBV genome. However, a recent study noted that a transiently transfected plasmid containing BcLF1 promoter (but lacking the oriLyt of EBV) is expressed and regulated by lytic DNA replication (Serio et al., 1997) . Our results confirmed this finding, and indicated that without oriLyt the promoter of BcLF1 in plasmid pVCAluc is active under lytic conditions (Fig. 3 a) . However, if an oriLyt sequence (nt 52358-53819 of the EBV genome) was inserted downstream from BcLF1 in either orientation in pVCAluc, the resulting plasmids could transcribe the luciferase activity at a level approximately 17-to 40-fold higher than that of pVCAluc (Fig. 3 b, c) , thereby confirming that lytic DNA replication is crucial for enhancing expression of BcLF1.
In conclusion, we have identified the j1 site of BcLF1 mRNA by primer extension. Experimental results indicated that regulation of BcLF1 transcription requires a 23 bp sequence, from nucleotides k38 to k16, containing a TATA sequence only. Although BcLF1 expression can be regulated independently of lytic replication, the presence of an oriLyt can enhance expression of BcLF1.
